Review

Placental Ischemia Says “NO” to Proper NOS-Mediated Control of Vascular Tone and Blood Pressure in Preeclampsia

Ana C. Palei 1, Joey P. Granger 2 and Frank T. Spradley 1,2,3,*

1 Department of Surgery, University of Mississippi Medical Center, Jackson, MS 39216, USA; apalei@umc.edu
2 Department of Physiology & Biophysics, University of Mississippi Medical Center, Jackson, MS 39216, USA; jgranger@umc.edu
3 Department of Pharmacology & Toxicology, University of Mississippi Medical Center, Jackson, MS 39216, USA
* Correspondence: fspradley@umc.edu

Abstract: In this review, we first provide a brief overview of the nitric oxide synthase (NOS) isoforms and biochemistry. This is followed by describing what is known about NOS-mediated blood pressure control during normal pregnancy. Circulating nitric oxide (NO) bioavailability has been assessed by measuring its metabolites, nitrite (NO$_2$) and/or nitrate (NO$_3$), and shown to rise throughout normal pregnancy in humans and rats and decline postpartum. In contrast, placental malperfusion/ischemia leads to systemic reductions in NO bioavailability leading to maternal endothelial and vascular dysfunction with subsequent development of hypertension in PE. We end this article by describing emergent risk factors for placental malperfusion and ischemic disease and discussing strategies to target the NOS system therapeutically to increase NO bioavailability in preeclamptic patients. Throughout this discussion, we highlight the critical importance that experimental animal studies have played in our current understanding of NOS biology in normal pregnancy and their use in finding novel ways to preserve this signaling pathway to prevent the development, treat symptoms, or reduce the severity of PE.

Keywords: intrauterine growth restriction; nitric oxide; nitric oxide synthases; potential therapies; preeclampsia; pregnancy

1. Introduction

The number of hypertensive pregnancies has been on the rise over the past several decades. Hypertension is a leading complication during pregnancy in the United States and throughout the world. One particularly dangerous form is preeclampsia (PE), which in addition to new-onset hypertension, is diagnosed alongside other co-morbidities including proteinuria, oliguria, pulmonary edema, epigastric pain, impaired liver function, thrombocytopenia, headaches, oligohydramnios, placental abruption, and/or fetal growth restriction occurring during the latter half of pregnancy [1]. PE can be classified into two subtypes of early- or late-onset, with a greater number of diagnostic co-morbidities being an index of the severity of PE. More severe forms of PE are associated with maternal blood pressure reaching $>160/110$ mmHg, and the rate of PE with severe features is rising [2]. PE not only has immediate outcomes leading to maternal and/or fetal morbidity and mortality, but also has long-term ramifications with increased risk for future cardiovascular disease in formerly-preeclamptic women and their offspring [3,4]. Overall, the diverse features and continued immediate and long-term impacts of PE highlight our lack of a full appreciation of the organ systems and mechanisms involved in the development of hypertension in PE.

A pregnancy-specific organ implicated in the progression of PE is the diseased placenta. The placenta is highly-vascularized and is the site where nutrient and waste exchange occur to ensure proper fetal growth. Placentalent involves invasion of fetal-derived trophoblast cells that promote decidualization of the uterus with remodeling and widening of the
maternal spiral arteries, as reviewed in [5]. Damage to the fetal-derived trophoblast cells that reside in the placenta and decidualized uterus is thought to mediate and propagate the maternal vascular dysfunction and hypertensive outcomes in PE, regardless of its gestational age of presentation [6,7]. Such damage can result from multiple factors, including malperfusion and resultant placental ischemia. A method by which this is measured is Doppler ultrasound with the observation of dicrotic notches in the pulse wave signal of the uterine artery during PE [8]. This notching is indicative of an increased uterine vascular resistance index (UARI) [9]. Uteroplacental ischemia is detected in PE, especially with more severe forms [10]. Placental ischemia/hypoxia elicits the release of factors that target the endothelium and reduce the ability of maternal nitric oxide synthase (NOS) to modulate vascular tone and blood pressure.

In this review, we first provide a brief overview of the NOS isoforms and biochemistry of these enzymes. This is followed by describing what is known about NOS-mediated blood pressure control during normal pregnancy. Indeed, circulating nitric oxide (NO) bioavailability has been assessed by measuring its metabolites, nitrite (NO$_2$), and/or nitrate (NO$_3$), and shown to rise throughout normal pregnancy in humans and rats [11–14] and decline postpartum [15,16]. In contrast, placental ischemia leads to systemic reductions in NO bioavailability leading to maternal endothelial and vascular dysfunction with subsequent development of hypertension in PE [17]. We end this article by describing emergent risk factors for placental malperfusion and ischemic disease and discuss strategies to therapeutically target the NOS system to increase NO bioavailability in preeclamptic patients. Throughout this discussion, we highlight the critical importance that experimental animal studies have played in our current understanding of NOS biology in normal pregnancy and their use in finding novel ways to preserve this signaling pathway to prevent the development, treat symptoms, or reduce the severity of PE.

2. NOS Isoforms and Biochemistry

NO is a ubiquitous gaseous and lipophilic molecule involved in a variety of biological processes. NO is generated from the conversion of L-arginine to L-citrulline. In mammals, this reaction is catalyzed by three isoforms of the enzyme nitric oxide synthase: neuronal (NOS1), inducible (NOS2), and endothelial (NOS3). An overview of the NOS structure, regulation, and function have been reviewed in depth elsewhere [18–20]. But briefly, each NOS enzyme is encoded by a different gene, with 51–57% homology between the isoforms. They have different cell localization, regulation, catalytic properties, and inhibitor sensitivity. NOS1 and NOS3 are constitutively expressed, usually producing low concentrations of NO for paracrine signaling related mainly to neurotransmission and cardiovascular homeostasis (control of vascular tone, cellular proliferation, leukocyte adhesion, and platelet aggregation). Whereas, NOS2 expression is induced by cytokines and typically generates high concentrations of NO for modulation of inflammatory responses, host defense against pathogens, and airway epithelial formation. Yet, numerous other stimuli may regulate NOS at the transcriptional, posttranscriptional, and posttranslational levels. In this regard, variations in the nucleotide sequence of the NOS genes have been reported to alter NOS synthesis and activity. Consequently, these genetic polymorphisms may affect NO production. For instance, haplotypes formed by the combination of the NOS3 polymorphisms T-786C in the promoter region, G894T in exon 7 (Glu298Asp), and a 27 bp variable number of tandem repeats (VNTRs) α/β in intron 4 have been associated with susceptibility to the development of disease, decreased circulating NO levels, and lack of response to antihypertensive treatment in PE [21].

In its active form, NOS is a homodimer where each subunit is composed of a C-terminal reductase domain, which comprises the binding sites for nicotinamide adenine dinucleotide phosphate (NADPH), flavin mononucleotide (FMN), and flavin adenine dinucleotide (FAD), and by an N-terminal oxygenase domain, which contains binding sites for heme, zinc, tetrahydrobiopterin (BH4), and L-arginine. Between the reductase and oxygenase domains, there is a calmodulin-binding sequence. While the Ca$^{2+}$-calmodulin
In its active form, NOS is a homodimer where each subunit is composed of a C-terminal oxygenase domain, which contains binding sites for nicotinamide adenine dinucleotide (NADPH), flavin mononucleotide (FMN), and flavin adenine dinucleotide domains, there is a calmodulin-binding sequence. While the Ca\(^{2+}\)-calmodulin complex is necessary to activate NOS1 and NOS3, NOS2 is already bound to calmodulin and does not depend on Ca\(^{2+}\) to be fully active. In the final steps of NO formation, NOS flavins transfer electrons from NADPH to the heme; molecular oxygen binds to heme, and is then incorporated into L-arginine to form NO and L-citrulline. Binding of NOS substrates and cofactors must be finely controlled in order for NO to be efficiently produced. Disruption of this highly coordinated reaction impairs NOS activity. Indeed, limited quantities of substrate and cofactors or excess amounts of endogenous inhibitors, such as asymmetric dimethyl-L-arginine (ADMA) and monomethyl-L-arginine (L-NMMA), may lead to a shift from the dimeric to monomeric form of the enzyme. When uncoupled, NOS generates superoxide anion instead of NO. Furthermore, the interaction of NO with superoxide anion yields peroxynitrite and this highly toxic compound reacts with DNA, proteins, and lipids to cause oxidative stress. On the other hand, oxidative stress enhances the expression of arginase, an enzyme that degrades L-arginine into ornithine and urea. In PE, there is evidence of increased arginase activity, elevated ADMA and superoxide levels, and post-translational modifications of NOS3 by lipid peroxidation aldehydes, all resulting in impaired NOS activity and reduced NO bioavailability [22].

NO produced by endothelial cells diffuses to surrounding platelets and the vascular smooth muscle cell (VSMC) layer where it binds to the heme moiety of soluble guanylate cyclase (sGC). sGC serves as the receptor for NO (Figure 1). sGC is an enzyme that catalyzes the conversion of guanosine triphosphate into cyclic guanosine monophosphate (cGMP). While cGMP inhibits platelet reactivity, it triggers the phosphorylation of multiple cell proteins and lower intracellular free calcium concentrations in VSMC, promoting vascular relaxation. Downstream in the cascade of NO/cGMP pathway are phosphodiesterases (PDE), a family of enzymes responsible for regulating the localization, duration, and amplitude of cyclic nucleotide signaling within the cell. PDE-5 is of particular importance for the degradation of cGMP in VSMC, thereby influencing vascular contractile tone [23].

![Figure 1. Schematic representation of the cascade of events leading from trophoblast dysfunction and cellular stress to subsequent abnormalities in uteroplacental vascular remodeling, malperfusion, and ischemia. These ischemia/hypoxic events elicit the release of anti-angiogenic and pro-hypertensive factors, like soluble Fms-like tyrosine kinase (sFlt-1), into the maternal circulation. This factor can feedback to reduce cellularity of the placenta, and reduce uteroplacental vascularity [24]. sFlt-1 can also quench vasodilatory factors, like PIGF, which are important for maternal vascular health. This ultimately leads to systemic reductions in nitric oxide (NO) bioavailability and endothelial dysfunction. Reduced NO has less capacity to activate its receptor, soluble guanylate cyclase (sGC),](attachment:Figure_1.png)
and production of the second messenger cyclic guanosine monophosphate (cGMP) resulting in maternal vascular dysfunction, hypertension, and intrauterine growth restriction (IUGR). In red font is the proposal that administration of NOS substrates or cofactors; modulators of sGC; or blocking the breakdown of cGMP with inhibitors of phosphodiesterase (PDE)-5 could be utilized to prevent the development, treat symptoms, or reduce the severity of PE.

3. NOS-Mediated Control of Renal and Systemic Vascular Function and Blood Pressure Regulation in Normal Pregnancy

There are dramatic hemodynamic changes that occur during normal pregnancy encompassing progressive progressive renal blood flow to allow for plasma volume expansion (PVE) and blood flow of nutrients to the growing uteroplacental–fetal unit [25]. This is accompanied by maintained or reduced maternal blood pressure by term [16]. NOS largely governs these physiological adaptations [26,27], whereby PVE is mediated by distinct local changes in renal NO signaling [28]. Urinary NOx, as a measure of renal NO production, progressively rises during gestation in normal pregnant rats [16]. NOS mediates the increased renal blood flow during pregnancy. This would typically promote sodium excretion but not during pregnancy because of attenuated renal tubular NO signaling due to increased PDE-5 activity to degrade the NO second messenger, cGMP [28]. Collectively, this attenuates the natriuretic effects of NO to allow for continued sodium reabsorption and PVE in the face of increased renal blood flow during normal pregnancy. This point has been demonstrated by studies using chronic administration of non-selective NOS inhibitors, like N(gamma)-nitro-L-arginine methyl ester (L-NAME). L-NAME dosing during early pregnancy attenuated the elevations in glomerular filtration (GFR), renal plasma flow (RPF), and PVE towards the end of pregnancy in rats [13,29].

L-NAME has multiple systemic effects during pregnancy. L-NAME administration in rats prevents the fall in systemic vascular resistance by mid-gestation [13]. At that time point, maternal blood pressure is not significantly different between non-pregnant, normal pregnant, or pregnant + L-NAME groups. However, it was found in a separate study that later administration of L-NAME from gestational days 13–19 produced a profound hypertensive response by the end of pregnancy. In this study, the pregnant rats had a greater degree of blood pressure elevation than did their non-pregnant counterparts [25] (Figure 2). Similarly, NOS inhibition from gestational days 7–20 promoted hypertension and reduced PVE in pregnant rats [29]. Recent data suggest that reduced PVE causes the uterine circulation to compensate for uteroplacental malperfusion by increases in NO-mediated vasodilation [30]. Nevertheless, this may not be sufficient to fully prevent the placental apoptosis that accompanies NOS inhibition during pregnancy [31], as the barotrauma of hypertension seems to feed forward to reduce uterine vascular blood flow in L-NAME-hypertensive pregnant rats [32].

![Figure 2. Impact of non-selective NOS inhibition with L-NAME on conscious maternal mean arterial blood pressure (MAP). L-NAME was administered in pregnant rats from gestational day 13–19 in drinking water (Vehicle). * p < 0.05 for virgin vs. pregnant vehicle-treated rats; ** p < 0.05 for pregnant + vehicle vs. pregnant + L-NAME rats. Mean ± SEM. Data adapted from [25].](image-url)
The above studies utilized a pharmacological means to non-selectively inhibit the NOS enzymes, with agents such as L-NAME, during pregnancy. However, differential expression of the NOS isoforms has been reported during normal pregnancy. NOS3 protein expression progressively declines but NOS1 and NOS2 increase in the kidney during pregnancy in rats [16]. In order to define the specific role of individual NOS isoforms on maternal vascular function and blood pressure regulation during pregnancy, knockout-mouse experiments were required. Each NOS isoform has been knocked out and maternal and fetal outcomes examined to some extent. NOS3-knockout pregnant mice have reduced uterine blood flow toward the end of gestation [33] and elevated blood pressure measured via telemetry [34]. However, differing results have been reached using tail-cuff plethysmography with no difference or elevated systolic blood pressure compared to wild-type controls [35,36]. Results also indicate that NOS3-knockout mice had attenuated uterine artery diameter, uterine blood flow, and spiral artery remodeling along with signs of placental ischemia and reduced fetal weight [33]. It was found that NOS3 is an important signaling pathway whereby insulin-like growth factor 1 (IGF-1), which increases during normal pregnancy [37], promotes fetal growth [38].

In consideration of the other NOS isoforms, a study examined the impact of singly knocking out each and found no alteration in maternal blood pressure when measured by tail-cuff [35]. Moreover, the number of viable offspring was not altered by single-knockout of the individual NOS isoforms; but double-knockout of any two NOS genes reduced offspring number to a similar extent; and the triple-knockouts had further reductions in this pregnancy outcome [39]. Unfortunately, pregnancy was not a major focus of that study, and thus, a more in-depth examination of placentation, trophoblast viability, uteroplacental vascular outcomes, fetal growth restriction, and maternal blood pressure were not examined following the different permutations of knocking out the NOS isoforms.

The earlier genetic strategies manipulating the expression of each NOS isoform have a caveat due to the fact that there are splice variants of NOS1, including NOS1-α, -β, and -γ [40]. The older NOS1 knockout studies only targeted NOS1-α expression [41]. Recent research has led to the development of NOS1-β knockouts that revealed important mechanisms for intrarenal control of systemic blood pressure during pregnancy [42].

As mentioned, normal pregnancy is accompanied by tremendous vasodilation noted by increases in GFR and RPF. Elevations in GFR during normal pregnancy are mediated by attenuated tubuloglomerular feedback (TGF). This allows for glomerular hyperfiltration even though there is lower chloride, which is owed to PVE, delivered to salt-sensing cells in the distal nephron, called the macula densa [43,44]. This would typically activate a negative-feedback loop to stabilize the tubular flow reaching the macula densa and allow for proper sodium excretion. This process is mediated via increased NOS1-β signaling in the macula densa, whereby in the non-pregnant state, macula densa-specific NOS1-β-knockout mice have enhanced TGF and fail to increase GFR in response to acute volume expansion producing a salt-sensitive hypertension phenotype [45]. During normal pregnancy, expression of NOS1-β in the macula densa increases in rodents and humans, and its knockout leads to enhanced TGF, decreased GFR, and causes hypertension to mimic the blood pressure phenotype in preeclamptic women [42].

It is not yet fully known what drives the increase in macula densa NOS1 during normal pregnancy, but pregnancy-specific rises in hormones could be responsible. This includes relaxin, which is produced from the ovaries and placenta. Relaxin administration increased renal NO metabolite excretion, but this was examined only in male rats [46]. Relaxin is reduced in preeclamptic women [47]. The impact of relaxin on blood pressure regulation has been examined in a preclinical model of PE, namely the Reduced Uterine Perfusion Pressure (RUPP) rat model. This model is produced by strategically placing silver clips around blood vessels within the pregnant uterus, eliciting uteroplacental malperfusion and placental ischemia-induced hypertension. RUPP rats have many similarities to women with PE [48]. Administration of a recombinant form of human relaxin-2, named serelaxin, increased plasma NOx and attenuated the development of hypertension in RUPP rats [49].
However, it has not yet been examined how serelaxin impacts renal NOS expression or NOx excretion, especially as RUPP rats have a downregulation of NOS1-β in the macula densa [42]. As NOx is reduced in PE, the next section will explore evidence to support that maternal NO bioavailability is attenuated by soluble placental ischemic factors to promote hypertension in PE.

4. Soluble Placental Ischemic Factors and Reduced NO in PE

Studies conducted since the 1990s have shown that plasma and 24 h urinary NOx or cGMP are reduced or do not rise in women with PE compared to normal pregnancy [50,51]. These metabolites are important to measure because they not only provide an indication of NO bioavailability, but nitrite has a biological activity to promote vasorelaxation in human placental vessels [52]. Within the past 5 years, the majority of studies have shown that preeclamptic women and experimental animal models have reduced measures of circulating NO bioavailability, like NOx, and lower levels of NOS3 (Table 1). Moreover, in vivo techniques to assess vascular function have demonstrated that women with PE have vascular dysfunction [53,54] and increased vascular resistance [55]. This vascular dysfunction is associated with circulating levels of placental ischemic, hypertensive factors, such as increased serum soluble fms-like tyrosine kinase (sFlt-1). Elevated sFlt-1 quenches the vasodilatory capacity of vascular endothelial growth factor (VEGF) and placental growth factor (PIGF). NOS largely contributes to this dilatory response in uterine arteries isolated from late-pregnant rats [56]. An elevated sFlt-1:PIGF ratio is a biomarker for those women that are more at risk for PE with severe features [54,57].

Table 1. PubMed search results for keywords “nitric oxide” AND “preeclampsia” form 2015-pr. Arrows represent the direction of change (↑, increased; ↓, decreased), and equal signs (=) represent no change in NOS expression/NO biomarkers (NOx).

| Species/Experimental Model | Circulating | Tissue |
|---------------------------|-------------|--------|
| Human                     |             |        |
|                           | Shaheen G. et al. [58] ↓ NOx | Blood vessels: Lorca R.A. et al. [73] ↓ NOS function |
|                           | Possomato-Vieira J.S. et al. [59] ↓ NOx | Primary HUVECs: Chen J. et al. [74] ↓ NOS3 |
|                           | Pereira D.A. et al. [60] ↓ NOx | Salsoso R. et al. [75] ↓ NOS activity |
|                           | McCann Haworth S.M. et al. [61] ↓ NOx | Placenta: Mishra J.S. et al. [76] ↓ NOS3 |
|                           | Tashie W. et al. [62] ↓ NOx | K.-Y. Jung et al. [77] ↑ NOS2 |
|                           | Kim S. et al. [63] ↑ NOx | Kim S. et al. [63] ↑ NOS2, ↓ NOS3 |
|                           | Mazloomi S. et al. [64] ↓ NOS | Mukosera G.T. et al. [78] ↑ NOx |
|                           | Lai H. et al. [65] ↓ NOx | Shaheen G. et al. [79] ↓ NOS3 |
|                           | Ajadi I. et al. [66] ↓ NOx | Guerby P. et al. [80] ↓ NOS3 |
|                           | Serrano-Berrones et al. [67] ↓ NOx | Hitzerd E. et al. [81] ↑ maternal placenta NOS3, ↓ maternal placental NOS2, = fetal placenta |
|                           | Deniz R. et al. [68] ↓ NOx | NOS2, ↑ fetal placenta NOS2 |
|                           | Bos M. et al. [69] ↓ NOx | Guerby P. et al. [82] ↓ NOS3 |
|                           | ElMonier A.A. et al. [70] ↓ NOx | Li F.F. et al. [55] ↓ NOS2, NOS3 |
|                           | Hodzic J. et al. [71] ↓ NOx | Motta-Mejia C. et al. [83] ↓ NOS3 |
|                           | Rocha-Penha L. et al. [72] ↓ NOx | Du L. et al. [84] ↑ NOS2, ↓ NOS3 |
|                           | Bambrana V. et al. [15] ↓ NOx |        |
|                           | Lai H. et al. [65] ↓ NOx |        |

Non-human primate/Early Pregnancy Excess of Estradiol | Albrecht E.D. et al. [85] ↓ NOx | Blood vessels: Albrecht E.D. et al. [85] ↓ NOS3 |
Table 1. Cont.

| Species/Experimental Model | Circulating | Tissue |
|---------------------------|-------------|--------|
| Rat/RUPP                  |             |        |
| Travis O.K. et al. [86]  | ↓ NOx       |        |
| Palei A.C. et al. [17]   | ↓ NOx       |        |
| Cottrell J.N. et al. [87] | ↓ NOx      |        |
| El-Saka M.H. et al. [88] | ↓ NOx      |        |
| Wang C. et al. [89]      | ↓ NOx       |        |
| Amaral L.M. et al. [90]  | ↓ NOx       |        |
| Jammalamadaga V.S. et al. [91] | ↓ NOx |        |
| Santiago-Font J.A. et al. [49] | ↓ NOx |        |
| Blood vessels:           |             |        |
| Younes S.T. et al. [92]  | = NOS3      |        |
| Ma S.L. et al. [93]      | ↓ NOx, NOx  |        |
| Zhu M. et al. [94]       | ↓ NOS3      |        |
| Placenta:                |             |        |
| Tengfei Z. et al. [95]   | ↓ NOS3, ↑ NOS2 |    |
| Wang C. et al. [89]      | ↓ NOS3      |        |
| Mouse/AntiphospholipidSyndrome |     |        |
| Lefkou E. et al. [100]   | ↓ NOx       |        |
| Blood vessels:           |             |        |
| Mismatch [67]            | ↓ NOx       |        |
| Tyurenkov I.N. et al. [74] | ↓ NOS3, ↑ NOS2 |    |
| Rat/DOCA-salt            |             |        |
| Wang G.-J. et al. [96]   | ↓ NOx       |        |
| Blood vessels:           |             |        |
| Chimini J.S. et al. [97] | ↓ NOS3      |        |
| Mouse/Progranulin Deficiency |     |        |
| Xu B. et al. [103]       | ↓ NOS3      |        |
| Mouse/Hypoxia Chamber    |             |        |
| Lane S.L. et al. [104]   | ↓ NOS function |    |
| Mouse/sFlt-1 Adenovirus  |             |        |
| Blood vessels:           |             |        |
| Zhang S. et al. [105]    | ↓ NOS3      |        |

In the experimental animal setting, models generated by reducing uterine perfusion or by producing chronic excess of exogenous placental ischemic factors, like sFlt-1, have been used to probe the severe features of PE. Experimental animal models ranging from nonhuman primates to rodents have been used to probe the severe features of PE. Experimental animal models ranging from nonhuman primates to rodents confirm that reductions in uteroplacental blood flow elicits placental ischemia/hypoxia-induced release of soluble factors that promote endothelial and vascular dysfunction and hypertension in PE [48,85,106,107]. Indeed, reducing sFlt-1 with siRNA technology attenuated uteroplacental ischemia-induced hypertension and proteinuria in pregnant baboons [108]. That study did not examine maternal NO bioavailability, but this has been touched upon in rodent models of PE. The infusion of sFlt-1 into once normotensive pregnant rats produced hypertension and reduced glomerular generation of NO, as measured by DAF fluorescence [109]. The precise mechanisms whereby this occurs are not fully clear, but sFlt-1 infusion into pregnant mice reduced systemic vascular mRNA expression of endothelin type B (ET\textsubscript{B}) receptors [110]. This receptor serves to mediate the vasodilatory action of the endothelium-derived vasoactive peptide, endothelin-1 (ET-1), by stimulating NOS enzymatic activity [111]. It has begun to be examined if reductions in ET\textsubscript{B} potentiate placental ischemia-induced hypertension. We have data to support that ET\textsubscript{B}-deficient rats have increased blood pressure by the end of pregnancy and this response is exaggerated in the face of the RUPP procedure [112].

Telemetric evidence supports the development of placental ischemia-induced hypertension in RUPP rats [113], which is accompanied by reduced NOS-mediated buffering of vascular tone and increased vasoconstriction [114]. Furthermore, we have shown that RUPP-hypertensive rats have elevated circulating sFlt-1 and administration of recombinant human PlGF prevented the development of their hypertension (Figure 3). This has been supported by others [94]. However, it has not been examined whether this anti-
hypertensive effect of PlGF is mediated by NOS, which could be studied by dosing with L-NAME. It could be that RUPP rats with complete NOS inhibition with L-NAME would present with more severe features of PE. Moreover, it is currently unknown whether a deficiency in any specific NOS isoform impacts the response to placental ischemia-induced hypertension. What is known is that NOS3-knockout mice have exaggerated hepatic dysfunction, thrombocytopenia, renal injury, and hypertension in response elevated sFlt-1 induced by adenoviral overexpression [115]. Together, these studies support that NOS deficiency exaggerates placental ischemia-induced hypertension, but far less is understood about whether this pathway is targeted to increase the risk for PE in the face of emerging cardiovascular disease risk factors.

Figure 3. Effects of treatment with recombinant human placental growth factor (rhPlGF) on blood pressure responses in pregnant rats with reduced uterine perfusion pressure (RUPP). Rats were subjected to the RUPP procedure on gestational day 14. Rats were administered rhPlGF (180 µg/kg per day, I.P. osmotic minipump) from gestational day 14–19. Conscious mean arterial blood pressure (MAP) was measured on day 19. p-Values appear in the above brackets. Mean ± SEM. Data adapted from [116].

5. Pro-Inflammatory States as Risk Factors for Placental Ischemic Disease and PE

A major risk factor for PE is obesity [117]. Obesity is known as a pro-inflammatory state [118]. Women with combined obesity and PE have greater blood pressure levels and markers of increased inflammation measured by members of the tumor necrosis factor (TNF) family of proteins [119]. Adverse diets are a cause of obesity. A pro-inflammatory diet, in addition to perceived psychological stress, is associated with greater circulating TNF-α in pregnant women [120]. High-fat diet feeding results in elevated TNF-α levels and expression of the pro-inflammatory NOS isoform, NOS2, in placentas from pregnant mice [121–123]. There is conflicting data about NOS2 expression in placentas isolated from obese women [124,125]. However, maternal blood pressure is not always a focus of such studies. It has been shown that administering the NOS2 inhibitor, 1400 W, prevented RUPP-induced hypertension in rats [126]. NOS2 has been found to be increased in women with PE (Table 1).

Another inflammatory pathway studied in PE is the complement system. This system is important to “complement” the ability of antibodies and phagocytic cells to effectively remove microbes and apoptotic debris before they are able to release pro-inflammatory molecules. There are numerous small proteins involved in the complement signaling cascade. Notably, one such protein is C1q, which is expressed by trophoblast cells [127]. Deficiency of C1q in mice resulted in attenuated placental development and vascular remodeling. Further evidence that C1q expressed by trophoblast cells is important was demonstrated by the finding that paternal deficiency alone, and not the maternal deficiency of C1q, resulted in a PE-like phenotype in wild-type female mice presenting with increased blood pressure, increased fetal demise, and systemic vascular dysfunction during late-pregnancy [128,129]. Here, circulating sFlt-1 nor PlGF levels were altered at mid- or late-pregnancy. However, it was found that sFlt-1 levels in serum were higher when
both male and female breeders were deficient in C1q [129]. Circulating levels of C1q are lower in women with PE [130]. C1q is involved in the classical pathway of complement function, but overactivation of proteins associated with alternative, pro-inflammatory complement signaling, including C3a, have been shown to mediate the development of placental ischemia-induced hypertension in the RUPP rat [131].

Dysfunctional signaling within the complement cascade is associated with loss of self-tolerance and autoimmunity [132]. The autoimmune disease, systemic lupus erythematosus (SLE), has a propensity to affect women of reproductive age and increases the chance of complications during pregnancy, like PE [133]. It has been found that there is an increased sFlt-1:PlGF ratio during early pregnancy in women with SLE [134], which is indicative of placental ischemic disease in the face of maternal inflammation.

There is more support that maternal infection increases the incidence of placental ischemia and the onset of severe PE. One type of infection that is currently very prominent is exposure to the SARS-CoV-2 coronavirus, the cause for COVID-19. It has been linked to a greater risk for severe PE [135–138]. It was recently reviewed that almost 38% of pregnancies infected by COVID-19 have markers of uteroplacental malperfusion, including fibrin deposition, infarction, decidual vasculopathy, accelerated villous hyperplasia, distal villous hypoplasia, and retroplacental hemorrhage, as well as placental inflammation [139,140].

Placental malperfusion with ischemia/hypoxia not only elicits placental and maternal pro-inflammatory factors like TNF-α and agonistic autoantibodies to vasoconstrictor systems, like the angiotensin II type 1 receptor (AT1-AA) and α-adrenergic receptor, but also results in significant increases in placental and plasma levels of sFlt-1 [5]. TNF-α infusion increases blood pressure and circulating levels of sFlt-1 and AT1-AA in rats [141]. However, lacking is an optimal way to intervene in the signaling of these pro-inflammatory factors. These factors are consistently associated with reduced maternal NO bioavailability. It has not been thoroughly explored whether strategies to increase NOS coupling attenuates the development of PE.

6. Potential Treatment Strategies Targeting to Increase NO Bioavailability in PE

Treatment strategies have been tested in the settings of PE, attempting to increase NO bioavailability. In this section, we briefly summarize studies in humans and experimental animals evaluating potential therapies targeting the NOS system for ameliorating placental and/or vascular dysfunction in PE, with a focus on supplementation of NOS substrates and/or cofactors, modulators of sGC, and inhibitors of PDE-5. The role of NO donors, including organic nitrates and S-nitrosothiols, to attempt to prevent and ameliorate the clinical manifestation of PE has been extensively reviewed elsewhere [142,143].

6.1. L-Arginine Supplementation

L-arginine levels determined by chromatographic methods have been found to be reduced in maternal and umbilical cord plasma of preeclamptic women [144–147]. When assessed in the first trimester of gestation, plasma L-arginine levels were decreased in those women developing early-onset PE [148]. Promisingly, clinical studies demonstrated that intravenous and/or oral treatment with L-arginine improves many features of PE, such as hypertension, pre-term birth, and low birth weight [149–152]. In addition, L-arginine supplementation initiated anytime from 14 to 32 weeks of gestation significantly prevented the development of PE in patients deemed at risk for this syndrome [153,154]. However, few placebo-controlled trials reported no beneficial effects of L-arginine supplementation in PE [155,156], possibly due to differences in treatment initiation, dosage, and duration. Nonetheless, meta-analyses including these and additional studies concluded that L-arginine is superior to placebo in lowering blood pressure and prolonging pregnancy in women with established PE as well as in reducing the incidence of PE in high-risk women [157,158]. Studies in experimental animals also support the human data showing that treatment with L-arginine ameliorates hypertension during pregnancy [109,159–161].
For instance, 2% L-arginine added to the drinking water of RUPP rats or sFlt-1-infused pregnant rats significantly decreased their blood pressure levels, likely by increasing NO bioavailability and downregulating renal endothelin-1 expression [109,159]. These studies provide evidence that L-arginine supplementation during pregnancy is safe and may be used as a preventive and/or therapeutic tool in PE. As such, larger randomized double-blinded trials examining L-arginine supplementation in PE should be encouraged.

6.2. BH4 Supplementation

Scarce studies have assessed BH4 in PE. Kukor et al. found that, although BH4 levels were similar in placental tissue of PE and normal pregnant women, placental NOS3 activity exhibited two distinct responses to BH4 in PE: in placental homogenates from few PE patients (n = 3), the addition of physiological and higher concentrations of BH4 stimulated NOS3 activity similar to that of normal placental homogenates, whereas for the majority of PE placental homogenates (n = 7), only the addition of supraphysiological concentrations of BH4 caused significant NOS3 stimulation [162]. Using an animal model PE induced by injecting deoxycorticosterone acetate once a week and adding 0.9% saline to the drinking water (DOCA-salt) of female Sprague–Dawley rats before mating and during pregnancy, Mitchell et al. showed that ex vivo treatment with sepiapterin, a BH4 precursor, normalized decreased endothelium-dependent relaxation responses of mesenteric arteries, reduced NO, and increased superoxide and peroxynitrite levels of aortic tissue [163]. Similarly, incubation of mesenteric arteries with sepiapterin restored the decreased endothelium-dependent vasodilation of pregnant mice with deficiency of a copy of the cystathionine-beta synthase gene [164]. These heterozygous mice develop moderate hyperhomocysteinemia, a condition associated with PE and later cardiovascular disease [165–167]. Studies evaluating the in vivo effects of BH4 supplementation in PE have yet to be conducted in humans and experimental animals. However, clinical studies revealed that acute infusion of BH4 improved the impaired endothelium-dependent vasodilation in hypertensive patients to the level of normotensive counterparts [168]. Moreover, chronic oral treatment with 5 or 10 mg/kg/day of BH4 for 8 weeks, or 400 mg of BH4 in divided doses for 4 weeks, ameliorated endothelial function and blood pressure in human subjects with poorly controlled hypertension [169]. Studies in different animal models of chronic hypertension, such as those in spontaneously hypertensive rats, 5/6 nephrectomies rats, and angiotensin II-infused rats, reinforce that BH4 supplementation is able to improve hemodynamics and NO/cGMP signaling [170–175]. But, those studies did not focus on pregnancy hypertension. Overall, these findings suggest that BH4 supplementation deserves further consideration as a potential therapy for PE.

6.3. L-Citrulline Supplementation

Maternal and umbilical cord serum levels of L-citrulline have been reported to be similar in PE and normal pregnancy [149,176]. However, there is evidence arguing that circulating L-citrulline levels are reduced in women prone to develop recurrent PE [177] but elevated in women presenting severe PE [178]. Notably, L-citrulline content is decreased in human umbilical vein endothelial cells (HUVECs) isolated from late-onset preeclamptic women [75]. Nonetheless, L-citrulline instead of L-arginine has been proposed as a better supplementation strategy with regards to blood pressure and fetal growth because it bypasses hepatic first-pass metabolism and is converted to L-arginine within tissues [179,180]. L-citrulline supplementation has been tested in pregnant mice with deficiency of a copy of the complement component C1q gene, an animal model that exhibits pregnancy-specific vascular dysfunction, hypertension, proteinuria, and impaired fetal growth. The addition of 0.25% L-citrulline to the drinking water of these animals throughout gestation improved blood pressure, endothelium-dependent and -independent relaxation of mesenteric arteries, fetal weight, and placental efficiency [181]. L-citrulline supplementation in drinking water (2 g/kg/day, from gestational day 7 to 21) also increased fetal weight in a rat model of intrauterine growth restriction (IUGR) induced by maternal dietary protein restriction,
probably via enhanced NO production and expression of genes related to placental angiogenesis and survival [182,183]. Despite these preclinical studies showing that L-citrulline supplementation improves pregnancy outcomes, there are no human studies to date examining the impact of L-citrulline treatment on PE. Pooling data from randomized clinical trials, a recent meta-analysis performed by Barkhidarian et al. concluded that L-citrulline, when supplemented at a dose $\geq 6$ g/day, decreases both systolic and diastolic blood pressures in non-pregnant subjects [184]. Thus, future clinical studies should evaluate the effects of L-citrulline supplementation in PE.

6.4. Downstream Targets: sGC Stimulators, sGC Activators, and PDE-5 Inhibitors

Although the aforementioned studies investigating L-arginine, BH4, or L-citrulline as a therapeutic intervention in PE are promising, drugs targeting downstream mechanisms in the NO/cGMP pathway might be a better option for the treatment of preeclamptic women carrying functional alterations in the NOS3 gene. Several clinical studies associated NOS3 polymorphisms with increased risk of PE, which has been summarized by two recent meta-analyses confirming that the presence of the polymorphic allele at the 894 (T instead of G) position in the NOS gene predisposes pregnant women, especially those with Caucasian background, for the development of PE [185,186]. It has been previously shown that the G894T polymorphism affects NOS3 activity and cellular localization, leading to decreased NO formation in carriers of the T allele [187,188]. Indeed, the T allele for the G894T polymorphism has been associated with reduced circulating NO levels in both normal pregnancy and PE [189,190]. Additional studies have found that other commonly associated NOS3 polymorphisms with PE may also alter circulating NO levels [191,192]. Thus, in those situations where NOS activity is compromised by genetically driven defects, supplementation with substrates and/or cofactors might not act as expected, and alternative strategies should be explored.

Data regarding maternal blood/urine levels of cGMP in PE have been variable with studies describing reduced [51,61,193,194], elevated [195–199], or statistically unchanged levels [50,200–203]. Reduced cGMP levels are likely due to impaired NOS3 activity and decreased NO levels [51,61,194], whereas elevated cGMP levels may result from increased activation of sGC by atrial and/or brain natriuretic peptides in PE [196–199]. Nevertheless, it seems that sGC expression and activity are decreased in decidual and placental tissues collected from preeclamptic patients [204,205]. Studies in models of PE, including RUPP rats, pregnant rats administered the sulfonic acid, suramin, and the Dahl salt-sensitive rat model of superimposed PE corroborate findings in humans indicating that sGC expression, as well as cGMP levels, are reduced in blood vessels [206–208]. sGC stimulators and activators are a novel class of drugs that modulate sGC to increase cGMP production independently of NO. While sGC stimulators such as riociguat bind directly to the reduced, heme-containing form of the enzyme, sGC activators like cinaciquat bind to its oxidized, heme-free form [209]. Treatment of RUPP rats with an sGC activator added to the diet (BAY 60–2770, 16 ppm, ad libitum) from gestational day 14 to 19 restored their reduced cGMP levels and endothelial function of uterine arteries, reflecting on the amelioration of blood pressure [210]. Similar results were found along with improved uteroplacental blood flow, placental remodeling, and fetal growth were obtained by treating RUPP rats with daily subcutaneous injections of a sGC stimulator (riociguat, 10 mg/kg/day) from gestational day 14 to 20. However, sham pregnant rats undergoing the same therapy regimen with riociguat exhibited impaired uteroplacental blood flow and placental remodeling similar to vehicle-treated RUPP rats [206]. Follow-up studies revealed that, despite the effect of riociguat on prolonging pregnancy of RUPP rats, it worsened the probability of their babies surviving at birth and postnatal day 2. Moreover, riociguat treatment during late pregnancy did not mitigate RUPP-induced asymmetric IUGR and increased cardiovascular risk in male offspring at 4 months of age [211]. Importantly, although the US Food and Drug Administration (FDA) agency has approved riociguat (Adempas, Bayer) for the treatment of pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hyper-
tension (CTEPH), it is highlighted in its prescribing information that this medication has embryo-fetal toxicity and should not be administered to pregnant women. Thus, further studies in preclinical models of PE should be carried out to directly compare the maternal and fetal outcomes of sGC activators, stimulators, and PDE-5 inhibitors.

Reduced levels of cGMP in PE may also be due to increased PDE-5 activity. Indeed, clinical studies evaluating this cGMP-degrading enzyme in PE reported enhanced circulating PDE activity [212], with data in the rat RUPP model demonstrating increased PDE-5 expression in renal medullary and placental tissue [213]. Sildenafil and tadalafil have been tested clinically as PDE-5 inhibitors for the treatment of adverse pregnancy outcomes in PE. Earlier randomized controlled trials with sildenafil were promising, indicating beneficial effects on blood pressure, UARI, and duration of pregnancy in PE, with no increase in maternal or fetal morbidity and mortality [214–216]. In contrast, the Sildenafil Therapy in Dismal Prognosis Early Onset Fetal Growth Restriction (STRIDER) trial was prematurely terminated due to concerns that sildenafil may cause neonatal pulmonary hypertension, whereas benefit on perinatal mortality or major neonatal morbidity was unlikely [217,218]. Ferreira and collaborators’ meta-analysis evaluating sildenafil for the prevention or treatment of obstetric diseases concluded that it increases fetal weight at birth in the settings of placental insufficiency; however, they queried randomized clinical trials published up to September 2018, thereby not considering the results from the STRIDER trial [219]. Furthermore, a multicenter phase II clinical trial concluded that tadalafil, although safe, did not prolong pregnancy duration in PE [220]. A subsequent clinical study with preeclamptic patients treated with tadalafil found a dose-dependent increase in maternal mild adverse events (headache and palpitation), but all administered dosages were deemed safe for both mother and fetus [221]. Hence, a new meta-analysis should be performed, including the results of these recently published clinical trials on PDE-5 inhibitors in PE.

Numerous preclinical studies in PE have been conducted with sildenafil and tadalafil. Yet, most of these studies have utilized the mouse or rat L-NAME model. Although we agree that this animal model is valid and reiterates the importance of NOS on regulating placentation, vascular function, and blood pressure during pregnancy, it was already expected that the treatment of these animals with drugs targeting the same pathway being disturbed would lead to successful maternal and fetal outcomes [222–227]. Nonetheless, studies with catechol-O-methyl transferase knockout pregnant mice, RUPP rats, Dahl-salt sensitive rat model of PE agree with the findings in the mouse/rat L-NAME model, showing that sildenafil improves endothelial function, blood pressure, UARI, and fetal growth in PE [213,228,229]. Therefore, the use of PDE-5 inhibitors in PE is controversial and future studies should distinguish their effects between early- versus late-onset PE.

7. Summary and Conclusions

The maternal vascular endothelium appears to be an important target for factors involved in the pathophysiology of PE. The endothelium normally controls the balance between competing factors that ultimately impact vascular tone, coagulation, platelet function, and fibrinolysis. One endothelial factor that appears to play an important role in PE is NO. Not only does NO play an important role in the regulation of renal function and arterial pressure under various physiological and pathophysiological conditions, growing evidence suggests that reduced NO synthesis plays a central role in the pathophysiology of PE. In normal pregnancy, increased NO mediates renal vasodilation and decreases total peripheral resistance and blood pressure. However, in women with PE and in various animal models of PE, NO production is reduced, resulting in attenuated endothelium-dependent dilation, and the vasculature is hyper-responsive to a myriad of vasoconstrictive stimuli as a result of placental dysfunction. Some of these factors include sFlt-1, soluble endoglin, AT1-AA, and inflammatory cytokines.

Although there has been progress in understanding the mechanisms responsible for the pathogenesis of PE, effective therapeutic options for women that develop PE are still
not available. This review highlights the concept that agents that improve NOS coupling and signaling through sGC to directly target the endothelial dysfunction could serve as potential therapies to alleviate the maternal symptoms of PE to prolong pregnancy in severe PE (Figure 1). While preclinical studies in a number of animal models for studying PE have demonstrated beneficial effects of agents that impact NOS signaling, further investigation of the efficacy and safety of these agents is greatly needed.

Author Contributions: Conceptualization, A.C.P.; J.P.G. and F.T.S.; methodology, A.C.P., J.P.G. and F.T.S.; software, A.C.P., J.P.G. and F.T.S.; validation, A.C.P., J.P.G. and F.T.S.; formal analysis, A.C.P., J.P.G. and F.T.S.; investigation, A.C.P., J.P.G. and F.T.S.; resources, A.C.P., J.P.G. and F.T.S.; data curation, A.C.P., J.P.G. and F.T.S.; writing—original draft preparation, A.C.P., J.P.G. and F.T.S.; writing—review and editing, A.C.P., J.P.G. and F.T.S.; visualization, A.C.P., J.P.G. and F.T.S.; supervision, A.C.P., J.P.G. and F.T.S.; project administration, A.C.P., J.P.G. and F.T.S.; funding acquisition, A.C.P., J.P.G. and F.T.S.

All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by NIH grants: R01HL148191 (A.C.P.), P01HL051971 (J.P.G.), P20GM104357 (J.P.G.), U54GM115428 (J.P.G.), R00HL130577 (F.T.S.), P20GM121334 (F.T.S.), R56HL157579 (F.T.S.).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

References

1. The American College of Obstetricians and Gynecologists. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Obstet. Gynecol. 2013, 122, 1122–1131.

2. Ananth, C.V.; Keyes, K.M.; Wapner, R. Pre-eclampsia rates in the United States, 1980–2010: Age-period-cohort analysis. BMJ 2013, 347, f6564. [CrossRef] [PubMed]

3. Honigberg, M.C.; Riise, H.K.R.; Daltveit, A.K.; Tell, G.S.; Sulo, G.; Igland, J.; Klungsoyr, K.; Scott, N.S.; Wood, M.J.; Natarajan, P.; et al. Heart Failure in Women with Hypertensive Disorders of Pregnancy: Insights from the Cardiovascular Disease in Norway Project. Hypertension 2020, 76, 1506–1513. [CrossRef] [PubMed]

4. Andraweera, P.H.; Lassi, Z.S. Cardiovascular Risk Factors in Offspring of Preeclamptic Pregnancies—Systematic Review and Meta-Analysis. J. Pediatr. 2019, 208, 104–113.e6. [CrossRef] [PubMed]

5. Bakrania, B.A.; Spradley, F.T.; Drummond, H.A.; LaMarca, B.; Ryan, M.J.; Granger, J.P. Preeclampsia: Linking Placental Ischemia with Maternal Endothelial and Vascular Dysfunction. Compr. Physiol. 2020, 11, 1315–1349. [CrossRef]

6. Redman, C.W.; Staff, A.C.; Roberts, J.M. Syncitiotrophoblast stress in preeclampsia: The convergence point for multiple pathways. Am. J. Obstet. Gynecol. 2021. [CrossRef]

7. Pereira, M.M.; Torrado, J.; Sosa, C.; Zocalo, Y.; Bia, D. Role of arterial impairment in preeclampsia: Should the paradigm shift? Am. J. Physiol. Heart Circ. Physiol. 2021, 320, H2011–H2030. [CrossRef]

8. Espinoza, J.; Kusanovic, J.P.; Bahado-Singh, R.; Gervasi, M.T.; Romero, R.; Lee, W.; Vaisbuch, E.; Mazaki-Tovi, S.; Mittal, P.; Gotsch, F.; et al. Should Bilateral Uterine Artery Notching Be Used in the Risk Assessment for Preeclampsia, Small-for-Gestational-Age, and Gestational Hypertension? J. Ultrasound Med. 2010, 29, 1103–1115. [CrossRef]

9. Sharma, S.; Singh, S.; Gujral, U.; Oberoi, U.; Kaur, R. Uterine Artery Notching on Color Doppler Ultrasound and Roll over Test in Prediction of Pregnancy Induced Hypertension. J. Obstet. Gynecol. India 2011, 61, 649–651. [CrossRef]

10. Lisonkova, S.; Bone, J.N.; Muraca, G.M.; Razaz, N.; Wang, L.Q.; Sabr, Y.; Boutin, A.; Mayer, C.; Joseph, K. Incidence and risk factors for severe preeclampsia, hemolysis, elevated liver enzymes, and low platelet count syndrome, and eclampsia at preterm and term gestation: A population-based study. Am. J. Obstet. Gynecol. 2021. [CrossRef]

11. Darkwa, E.O.; Djagbletey, R.; Sottie, D.; Owoo, C.; Vanderpuye, N.M.; Essuman, R.; Aryee, G. Serum nitric oxide levels in healthy pregnant women: A case-control study in a tertiary facility in Ghana. Matern. Health Neonatol. Perinatol. 2018, 4, 3. [CrossRef]

12. Nascimento, R.A.; Possomato-Vieira, J.S.; Bonacic, G.F.; Rizzii, E.; Dias-Junior, C.A. Reductions of Circulating Nitric Oxide are Followed by Hypertension during Pregnancy and Increased Activity of Matrix Metalloproteinases-2 and -9 in Rats. Cells 2019, 8, 1402. [CrossRef] [PubMed]

13. Cadnapaphornchai, M.A.; Ohara, M.; Morris, K.G.; Knotek, M.; Rogachev, B.; Ladtkow, T.; Carter, E.P.; Schrier, R.W. Chronic NOS inhibition reverses systemic vasodilation and glomerular hyperfiltration in pregnancy. Am. J. Physiol. Physiol. 2001, 280, F592–F598. [CrossRef] [PubMed]
14. Deng, A.; Engels, K.; Baylis, C. Impact of nitric oxide deficiency on blood pressure and glomerular hemodynamic adaptations to pregnancy in the rat. *Kidney Int. 1996,* 50, 1132–1138. [CrossRef] [PubMed]

15. Bambrana, V.; Dayanand, C.D.; Kotur, P. Relationship between Xanthine Oxidase, Ischemia Modified Albumin, Nitric Oxide with Antioxidants in Non Pregnants, Pre and Post-delivery of Normal Pregnants and Preeclampsia. *Indian J. Clin. Biochem. 2016,* 32, 171–178. [CrossRef] [PubMed]

16. Alexander, B.T.; Miller, M.T.; Kassab, S.; Novak, J.; Reckelhoff, J.F.; Kruckeberg, W.C.; Granger, J.P. Differential expression of renal nitric oxide synthase isoforms during pregnancy in rats. *Hypertension 1999,* 33, 435–439. [CrossRef] [PubMed]

17. Palei, A.C.; Martin, H.L.; Wilson, B.A.; Anderson, C.D.; Granger, J.P.; Spradley, F.T. Impact of hyperleptinemia during placental ischemia-induced hypertension in pregnant rats. *Am. J. Physiol. Circ. Physiol. 2021,* 320, H1949–H1998. [CrossRef] [PubMed]

18. Alderton, W.K.; Cooper, C.E.; Knowles, R.G. Nitric oxide synthases: Structure, function and inhibition. *Biochem. J. 2001,* 357, 593–615. [CrossRef]

19. Förstermann, U.; Sessa, W. Nitric oxide synthases: Regulation and function. *Eur. Heart J.* 2011, 33, 829–837. [CrossRef]

20. Oliveira-Paula, G.H.; Lacchini, R.; Tanus-Santos, J.E. Endothelial nitric oxide synthase: From biochemistry and gene structure to clinical implications of NOS3 polymorphisms. *Gene 2015,* 575, 584–599. [CrossRef]

21. Luizon, M.R.; Palei, A.C.; Cavalli, R.C.; Sandrim, V.C. Pharmacogenetics in the treatment of pre-eclampsia: Current findings, challenges and perspectives. *Pharmacogenomics 2017,* 18, 571–583. [CrossRef] [PubMed]

22. Guerby, P.; Tasta, O.; Swiaeder, A.; Pont, F.; Bujold, E.; Parant, O.; Vaysseire, C.; Salvayre, R.; Negre-Salvayre, A. Role of oxidative stress in the dysfunction of the placental endothelial nitric oxide synthase in preeclampsia. *Redox Biol. 2021,* 40, 101861. [CrossRef] [PubMed]

23. Bobin, P.; Belacel-Ouari, M.; Bedioune, I.; Zhang, L.; Leroy, J.; Leblais, V.; Fischmeister, R.; Vandecasteele, G. Cyclic nucleotide phosphodiesterases in heart and vessels: A therapeutic perspective. *Arch. Cardiovasc. Dis. 2016,* 109, 431–443. [CrossRef]

24. Vogtmann, R.; Heupel, J.; Herse, F.; Matin, M.; Hagmann, H.; Bendix, I.; Kräcker, K.; Decherd, R.; Winterhager, E.; Kimmig, R.; et al. Circulating Maternal sFLT1 (Soluble fms-Like Tyrosine Kinase-1) Is Sufficient to Impair Spiral Arterial Remodeling in a Preeclampsia Mouse Model. *Hypertension 2021,* 78, 1067–1079. [CrossRef]

25. Kassab, S.; Miller, M.T.; Hester, R.; Novak, J.; Granger, J.P. Systemic hemodynamics and regional blood flow during chronic nitric oxide synthesis inhibition in pregnant rats. *Hypertension 1998,* 31, 315–320. [CrossRef]

26. Baylis, C. Cyclooxygenase products do not contribute to the gestational renal vasodilatation in the nitric oxide synthase inhibited pregnant rat. *Hypertens. Pregnancy 2002,* 21, 109–114. [CrossRef]

27. Conrad, K.P.; Colpoys, M.C. Evidence against the hypothesis that prostaglandins are the vasodopressor agents of pregnancy. Serial studies in chronically instrumented, conscious rats. *J. Clin. Investig. 1986,* 77, 236–245. [CrossRef]

28. Sasser, J.M.; Ni, X.-P.; Humphreys, M.H.; Baylis, C. Increased renal phosphodiesterase-5 activity mediates the blunted natriuretic response to a nitric oxide donor in the pregnant rat. *Am. J. Physiol. Physiol. 2010,* 299, F810–F814. [CrossRef]

29. Salas, S.P.; Altermatt, F.; Campos, M.; Giacaman, A.; Rosso, P. Effects of Long-term Nitric Oxide Synthesis Inhibition on Plasma Volume Expansion and Fetal Growth in the Pregnant Rat. *Hypertension 1995,* 26, 1019–1023. [CrossRef]

30. Bigonnese, E.; Sicotte, B.; Brochu, M. Activated NO pathway in uterine arteries during pregnancy in an IUGR rat model. *Am. J. Physiol. Circ. Physiol. 2018,* 315, H415–H422. [CrossRef] [PubMed]

31. Tsukimori, K.; Komatsu, H.; Fukushima, K.; Kaku, T.; Nakano, H.; Wake, N. Inhibition of Nitric Oxide Synthetase at Mid-gestation in Rats is Associated with Increases in Arterial Pressure, Serum Tumor Necrosis Factor-, and Placental Apoptosis. *Am. J. Hypertens. 2008,* 21, 477–481. [CrossRef]

32. Barron, C.; Mandala, M.; Oslo, G. Effects of Pregnancy, Hypertension and Nitric Oxide Inhibition on Rat Uterine Artery Myogenic Reactivity. *J. Vasc. Res. 2010,* 47, 463–471. [CrossRef] [PubMed]

33. Kulandavelu, S.; Whiteley, K.J.; Qu, D.; Mu, J.; Bainbridge, S.A.; Adamson, S.L. Endothelial Nitric Oxide Synthase Deficiency Reduces Uterine Blood Flow, Spiral Artery Elongation, and Placental Oxygenation in Pregnant Mice. *Hypertension 2012,* 60, 231–238. [CrossRef] [PubMed]

34. Li, F.; Hagaman, J.R.; Kim, H.-S.; Maeda, N.; Jennette, J.C.; Faber, J.E.; Karumanchi, S.A.; Smithies, O.; Takahashi, N. eNOS Deficiency Acts through Endothelin to Aggravate sFlt-1-Induced Pre-Eclampsia-Like Phenotype. *J. Am. Soc. Nephrol. 2012,* 23, 652–660. [CrossRef]

35. Shesely, E.G.; Gilbert, C.; Granderson, G.; Carretero, C.; Carretero, O.A.; Beierwaltes, W.H. Nitric oxide synthase gene knockout mice do not become hypertensive during pregnancy. *Am. J. Obstet. Gynecol. 2001,* 185, 1198–1203. [CrossRef]

36. Kulandavelu, S.; Qu, D.; Adamson, S.L. Cardiovascular Function in Mice During Normal Pregnancy and in the Absence of Endothelial NO Synthase. *Hypertension 2006,* 47, 1175–1182. [CrossRef] [PubMed]

37. Muhammad, A.; Neggers, S.J.; Van Der Lely, A.J. Pregnancy and acromegaly. *Pituitary 2016,* 20, 179–184. [CrossRef] [PubMed]

38. Wilson, R.L.; Troja, W.; Sumser, E.K.; Maupin, A.; Lampe, K.; Jones, H.N. Insulin-like growth factor 1 signaling in the placenta requires endothelial nitric oxide synthase to support trophoblast function and normal fetal growth. *Am. J. Physiol. Integr. Comp. Physiol. 2021,* 320, R653–R662. [CrossRef]

39. Morishita, T.; Tsutsui, M.; Shimokawa, H.; Sabanai, K.; Tasaki, H.; Suda, O.; Nakata, S.; Tanimoto, A.; Wang, K.-Y.; Ueta, Y.; et al. Nephrogenic diabetes insipidus in mice lacking all nitric oxide synthase isoforms. *Proc. Natl. Acad. Sci. USA 2005,* 102, 10616–10621. [CrossRef]
40. Hyndman, K.A.; Mironova, E.V.; Giani, J.F.; Dugas, C.; Collins, J.; McDonough, A.A.; Stockand, J.D.; Pollock, J.S. Collecting Duct Nitric Oxide Synthase Type I Activation Maintains Sodium Homeostasis during High Sodium Intake Through Suppression of Aldosterone and Renal Angiotensin II Pathways. *J. Am. Heart Assoc.* 2017, 6, e006896. [CrossRef]

41. Hyndman, K.; Boesen, E.; Elmarakby, A.A.; Brands, M.W.; Huang, P.; Kohan, D.E.; Pollock, D.M.; Pollock, J.S. Renal Collecting Duct NOS1 Maintains Fluid–Electrolyte Homeostasis and Blood Pressure. *Hypertension* 2013, 62, 91–98. [CrossRef] [PubMed]

42. Wei, J.; Zhang, J.; Jiang, S.; Xu, L.; Qu, L.; Pang, B.; Jiang, K.; Wang, L.; Intapad, S.; Buggs, J.; et al. Macula Densa NOS1beta Modulates Renal Hemodynamics and Blood Pressure during Pregnancy: Role in Gestational Hypertension. *J. Am. Soc. Nephrol.* 2021, 32, 2485–2500. [CrossRef] [PubMed]

43. Thomson, S.C.; Blantz, R.C. Ions and signal transduction in the macula densa. *J. Clin. Investig.* 2000, 106, 633–635. [CrossRef] [PubMed]

44. Baylis, C.; Blantz, R.C. Tubuloglomerular feedback activity in virgin and 12-day-pregnant rats. *Am. J. Physiol. Content* 1985, 249, F169–F173. [CrossRef] [PubMed]

45. Lu, Y.; Wei, J.; Stec, D.E.; Roman, R.J.; Ge, Y.; Cheng, L.; Liu, E.Y.; Zhang, J.; Hansen, P.B.; Fan, F.; et al. Macula Densa Nitric Oxide Synthase Ibeta Protects against Salt-Sensitive Hypertension. *J. Am. Soc. Nephrol.* 2016, 27, 2346–2356. [CrossRef]

46. Sasser, J.M.; Molnar, M.; Baylis, C. Relaxin ameliorates hypertension and increases nitric oxide metabolite excretion in angiotensin II but not N(omega)-nitro-L-arginine methyl ester hypertensive rats. *Hypertension* 2011, 58, 197–204. [CrossRef] [PubMed]

47. Uiterweer, E.D.P.; Koster, M.P.; Jeyabalan, A.; Kuc, S.; Siljee, J.E.; Stewart, D.R.; Conrad, K.P.; Franx, A. Circulating pregnancy hormone relaxin as a first trimester biomarker for preeclampsia. *Preparation Hypertens.* 2020, 22, 47–53. [CrossRef]

48. Bakrania, B.A.; George, E.M.; Granger, J.P. Animal models of preeclampsia: Investigating pathophysiology and therapeutic targets. *Am. J. Obstet. Gynecol.* 2021. [CrossRef]

49. Santiago-Font, J.A.; Amaral, L.M.; Faulkner, J.; Ibrahim, T.; Vaka, V.R.; Cunningham, M.W.; LaMarca, B. Serelaxin improves the pathophysiology of placental ischemia in the reduced uterine perfusion pressure rat model of preeclampsia. *Am. J. Physiol. Integr. Comp. Physiol.* 2016, 311, R1158–R1163. [CrossRef]

50. Conrad, K.P.; Kerchner, L.J.; Mosher, M.D. Plasma and 24-h NO(x) and cGMP during normal pregnancy and preeclampsia in women on a reduced NO(x) diet. *Am. J. Physiol.* 1999, 277, F48–F57. [CrossRef]

51. Baksu, B.; Davas, I.; Baksu, A.; Akyol, A.; Gulbaba, G. Plasma nitric oxide, endothelin-1 and urinary nitric oxide and cyclic guanosine monophosphate levels in hypertensive pregnant women. *Int. J. Gynecol. Obstet.* 2005, 90, 112–117. [CrossRef]

52. Tropea, T.; Wareing, M.; Greenwood, S.L.; Feelisch, M.; Sibley, C.P.; Cottrell, E.C. Nitrite mediated vasorelaxation in human chorionic plate vessels is enhanced by hypoxia and dependent on the NO(sGC-cGMP pathway. *Nitric Oxide* 2018, 80, 82–88. [CrossRef]

53. Mannaerts, D.; Faes, E.; Cornette, J.; Gyseelaers, W.; Spaanderman, M.; Goovaerts, I.; Stoop, T.; Roelant, E.; Jacquemyn, Y.; Van Craenenbroeck, E.M. Low-flow mediated constriction as a marker of endothelial function in healthy pregnancy and preeclampsia: A pilot study. *Preparation Hypertens.* 2019, 17, 75–81. [CrossRef]

54. Noori, M.; Donald, A.E.; Angelakopoulou, A.; Hingorani, A.; Williams, D. Prospective Study of Placental Angiogenic Factors and Maternal Vascular Function before and after Preeclampsia and Gestational Hypertension. *Circulation* 2010, 122, 478–487. [CrossRef] [PubMed]

55. Li, F.-F.; He, M.-Z.; Xie, Y.; Wu, Y.-Y.; Yang, M.-T.; Fan, Y.; Qiao, F.-Y.; Deng, D.-R. Involvement of dysregulated IKCa and SKCa channels in preeclampsia. *Placenta* 2017, 58, 9–16. [CrossRef]

56. Osol, G.; Celia, G.; Gokina, N.; Barron, C.; Chien, E.; Mandala, M.; Luksa, L.; Kubickiene, K. Placental growth factor is a potent vasodilator of rat and human resistance arteries. *Am. J. Physiol. Circ. Physiol.* 2008, 294, H1381–H1387. [CrossRef] [PubMed]

57. Perdigao, J.L.; Chinthala, S.; Mueller, A.; Minhas, R.; Ramadan, H.; Nasim, R.; Naseem, H.; Young, D.; Shahul, S.; Chan, S.L.; et al. Angiogenic Factor Estimation as a Warning Sign of Preeclampsia-Related Peripartum Morbidity among Hospitalized Patients. *Hypertension* 2019, 73, 486–877. [CrossRef] [PubMed]

58. Shaheen, G.; Jahan, S.; Bibi, N.; Ullah, A.; Faryal, R.; Al-Disi, D.; Abulmeaty, M.; Al Khuraif, A.A.; et al. Additional file 1 of Association of endothelial nitric oxide synthase gene variants with preeclampsia. *Reprod. Health* 2021, 18, 163. [CrossRef] [PubMed]

59. Possumato-Vieira, J.S.; Palei, A.C.; Pinto-Souza, C.C.; Cavalli, R.; Dias-Junior, C.A.; Sandrim, V. Circulating levels of hydrogen sulphide negatively correlate to nitrite levels in gestational hypertensive and preeclamptic pregnant women. *Clin. Exp. Pharmacol. Physiol.* 2021, 48, 1224–1230. [CrossRef] [PubMed]

60. Pereira, D.A.; Sandrim, V.C.; Palei, A.C.; Amaral, L.M.; Belo, V.A.; Lacchini, R.; Cavalli, R.C.; Tanus-Santos, J.E.; Luizon, M.R. NAMPT single-nucleotide polymorphism rs1319501 and visfatin/NAMPT affect nitric oxide formation, sFlt-1 and antihypertensive therapy response in preeclampsia. *Pharmacogenomics* 2021, 22, 451–464. [CrossRef] [PubMed]

61. Haworth, S.M.M.; Zhuge, Z.; Nihlén, C.; Von Rosen, M.F.; Weitzberg, E.; Lundberg, J.O.; Kmar, R.T.; Nasiell, J.; Carlström, M. Red blood cells from patients with pre-eclampsia induce endothelial dysfunction. *J. Hypertens.* 2021, 39, 1628–1641. [CrossRef] [PubMed]

62. Tashie, W.; Fondjo, L.A.; Owiredu, W.K.B.A.; Ephraim, R.K.D.; Asare, L.; Adu-Gyamfi, E.A.; Seidu, L. Altered Bioavailability of Nitric Oxide and L-Arginine Is a Key Determinant of Endothelial Dysfunction in Preeclampsia. *BioMed Res. Int.* 2020, 2020, 3251956. [CrossRef]
63. Kim, S.; Park, M.; Kim, J.-Y.; Kim, T.; Hwang, J.; Ha, K.-S.; Won, M.-H.; Ryoo, S.; Kwon, Y.-G.; Kim, Y.-M. Circulating miRNAs Associated with Dysregulated Vascular and Trophoblast Function as Target-Based Diagnostic Biomarkers for Preeclampsia. *Cells 2020*, *9*, 2003. [CrossRef] [PubMed]

64. Mazloomi, S.; Khodadadi, I.; Alimohammadi, S.; Shafiee, G. Correlation of thioredoxin reductase (TrxR) and nitric oxide synthase (NOS) activities with serum trace elements in preeclampsia. *Clin. Exp. Hypertens. 2020*, *43*, 120–124. [CrossRef] [PubMed]

65. Lai, H.; Nie, L.; Zeng, X.; Xin, S.; Wu, M.; Yang, B.; Luo, Y.; Liu, B.; Zhong, J.; Liu, H. Enhancement of heat shock protein 70 attenuates inducible nitric oxide synthase in preeclampsia complicated with fetal growth restriction. *J. Matern.-Neonatal Med. 2020*, 1–9. [CrossRef]

66. Ajadi, I.; Maduray, K.; Eche, S.; Gathiram, P.; Mackraj, I. Serum levels of vasoactive factors in HIV-infected pre-eclamptic women on HAART. *J. Obstet. Gynaecol. 2020*, *41*, 546–551. [CrossRef]

67. Serrano-Berrones, M.; Barragán-Padilla, S.B. Study on the association of hypertriglyceridemia with hypertensive states of pregnancy. *Gac. Med. Mex. 2019*, *155*, S17–S21. [CrossRef]

68. Deniz, R.; Baykus, Y.; Ustebay, S.; Ugur, K.; Yavuzkir, S.; Aydin, S. Evaluation of elabela, apelin and nitric oxide findings in maternal blood of normal pregnant women, pregnant women with pre-eclampsia, severe pre-eclampsia and umbilical arteries and venules of newborns. *J. Obstet. Gynaecol. 2019*, *39*, 907–912. [CrossRef]

69. Bos, M.; Schoots, M.H.; Fernandez, B.O.; Mikus-Leinski, M.; Lau, L.C.; Eikmans, M.; Van Goor, H.; Gordijn, S.J.; Pasch, A.; Feelsch, M.; et al. Reactive Species Interactome Alterations in Oocyte Donation Pregnancies in the Absence and Presence of Pre-Eclampsia. *Int. J. Mol. Sci. 2019*, *20*, 1150. [CrossRef]

70. ElMonier, A.A.; El-Boghdady, N.A.; Abdelaziz, M.A.; Shaheen, A.A. Association between endoglin/transforming growth factor beta receptors 1, 2 gene polymorphisms and the level of soluble endoglin in preeclampsia in Egyptian women. *Arch. Biochem. Biophys. 2018*, *682*, 7–14. [CrossRef]

71. Hodžić, J.; Izetbegović, S.; Muravečić, B.; Iriškić, R.; Jović, H. Nitric oxide biosynthesis during normal pregnancy and pregnancy complicated by preeclampsia. *Med. Glas. 2017*, 211–217. [CrossRef]

72. Rocha-Penha, L.; Caldeira-Dias, M.; Tanus-Santos, J.E.; Cavalli, R.D.C.; Sandrim, V.C. Myeloperoxidase in Hypertensive Disorders of Pregnancy and Its Relation with Nitric Oxide. *Hypertension 2017*, *69*, 1173–1180. [CrossRef]

73. Lorca, R.A.; Lane, S.L.; Bales, E.S.; Nsier, H.; Yi, H.; Donnelly, M.A.; Euser, A.G.; Julian, C.G.; Moore, L.G. High Altitude Reduces NO-Dependent Myometrial Artery Vasodilator Response During Pregnancy. *Hypertension 2019*, *73*, 1319–1326. [CrossRef]

74. Chen, J.; Gao, Q.; Jiang, L.; Feng, X.; Zhu, X.; Fan, X.; Mao, C.; Xu, Z. The NOX2-derived reactive oxygen species damaged endothelial nitric oxide system via suppressed BKCa/SKca in preeclampsia. *Hypertens. Res. 2017*, *40*, 457–464. [CrossRef]

75. Salsoso, R.; Mate, A.; Toledo, F.; Vázquez, C.M.; Sobrevia, L. Insulin requires A2B adenosine receptors to modulate the L-arginine/nitric oxide signalling in the human feto-placental vascular endothelium from late-onset preeclampsia. *Biochim. Biophys. Acta Mol. Basis Dis. 2020*, *1867*, 165993. [CrossRef] [PubMed]

76. Mishra, J.S.; Kumar, S. Activation of angiotensin type 2 receptor attenuates testosterone-induced hypertension and uterine vascular resistance in pregnant rats. *Gynecol. Oncol. Rep. 2021*, *105*, 192–203. [CrossRef] [PubMed]

77. Jung, K.-Y.; Uprety, L.P.; Jang, Y.-J.; Yang, J.I. Pro-inflammatory mediators and signaling proteins in the decidua of pre-eclampsia. *Eur. Rev. Med. Pharmacol. Sci. 2020*, *24*, 12016–12024. [PubMed]

78. Mukosera, G.T.; Clark, T.C.; Ngo, L.; Liu, T.; Schroeder, H.; Power, G.G.; Yellon, S.M.; Parast, M.M.; Blood, A.B. Nitric oxide metabolism in the human placenta during aberrant maternal inflammation. *J. Physiol. 2020*, *598*, 2223–2241. [CrossRef]

79. Shaheen, G.; Jahan, S.; Ain, Q.U.; Ullah, A.; Afsar, T.; Almajwal, A.; Alam, I.; Razak, S. Placental endothelial nitric oxide synthase expression and role of oxidative stress in susceptibility to preeclampsia in Pakistani women. *J. Matern.–Neonatal Med. 2020*, *34*, e1019. [CrossRef]

80. Guerby, P.; Siaudier, A.; Tasta, O.; Pont, F.; Rodriguez, F.; Parant, O.; Vaysseiere, C.; Shiba, T.; Uchida, K.; Salvayre, R.; et al. Modification of endothelial nitric oxide synthase by 4-oxo-2(E)-nonenal(ONE) in preeclamptic placentas. *Free Radic. Biol. Med. 2020*, *141*, 416–425. [CrossRef] [PubMed]

81. Hitzerd, E.; Broekhuizen, M.; Colafella, K.M.M.; Glisic, M.; de Vries, R.; Koch, B.C.; de Raaf, M.A.; Merkus, D.; Schoenmakers, S.; Reiss, I.K.; et al. Placental effects and transfer of sildenafil in healthy and preeclamptic conditions. *EBioMedicine 2020*, *416–425*. [CrossRef] [PubMed]

82. Guerby, P.; Siaudier, A.; Augé, N.; Parant, O.; Vaysseiere, C.; Uchida, K.; Salvayre, R.; Negre-Salvayre, A. High glutathionylation of placental endothelial nitric oxide synthase in preeclampsia. *Redox Biol. 2019*, *22*, 101126. [CrossRef] [PubMed]

83. Motta-Mejia, C.; Kandzija, N.; Zhang, W.; Mhlomi, V.; Cerdeira, A.S.; Burdúan, A.; Tannetta, D.; Dragovic, R.; Sargent, I.L.; Redman, C.W.; et al. Placental Vesicles Carry Active Endothelial Nitric Oxide Synthase and Their Activity is Reduced in Preeclampsia. *Hypertension 2017*, *70*, 372–381. [CrossRef]

84. Du, L.; He, F.; Kuang, L.; Tang, W.; Li, Y.; Chen, D. eNOS/iNOS and endoplasmic reticulum stress-induced apoptosis in the placentas of patients with preeclampsia. *J. Hum. Hypertens. 2016*, *31*, 49–55. [CrossRef] [PubMed]

85. Albrecht, E.D.; Babischkin, J.S.; Aberdeen, G.W.; Burch, M.G.; Pepe, G.J. Maternal systemic vascular dysfunction in a primate model of defective uterine spiral artery remodeling. *Am. J. Physiol. Circ. Physiol. 2021*, *320*, H1712–H1723. [CrossRef]

86. Travis, O.K.; Tardo, G.A.; Giachelli, C.; Siddiq, S.; Nguyen, H.T.; Crosby, M.T.; Johnson, T.; Brown, A.K.; Williams, J.M.; Cornelius, D.C. Tumor Necrosis Factor-Alpha Blockade Improves Uterine Artery Resistance, Maternal Blood Pressure, and Fetal Growth in Placental Ischemic Rats. *Pregnancy Hypertens. 2021*, *25*, 39–47. [CrossRef]
87. Cottrell, J.N.; Witcher, A.C.; Comley, K.M.; Cunningham, M.W., Jr; Ibrahim, T.; Cornelius, D.C.; LaMarca, B.D.; Amaral, L.M. Progestosterone-induced blocking factor improves blood pressure, inflammation, and pup weight in response to reduced uterine perfusion pressure (RUPP). Am. J. Physiol. Integr. Comp. Physiol. 2021, 320, R719–R727. [CrossRef]

88. El-Saka, M.H.; Madi, N.M.; Ibrahim, R.R.; Alghazaly, G.M.; Elshwaikh, S.; El-Bermawy, M. The ameliorative effect of angiotensin 1-7 on experimentally induced-preeclampsia in rats: Targeting the role of peroxisome proliferator-activated receptors gamma expression & asymmetric dimethylarginine. Arch. Biochem. Biophys. 2019, 671, 123–129. [CrossRef]

89. Wang, C.; Liu, X.; Kong, D.; Qin, X.; Li, Y.; Teng, X.; Huang, X. Apelin as a novel drug for treating preeclampsia. Exp. Ther. Med. 2017, 14, 5917–5923. [CrossRef]

90. Amaral, L.M.; Faulkner, J.L.; Elfarra, J.; Cunningham, M.W.; Ibrahim, T.; Vaka, V.R.; McKenzie, J.; LaMarca, B. Continued Investigation Into 17-OHPC: Results from the Preclinical RUPP Rat Model of Preeclampsia. Hypertension 2017, 70, 1250–1255. [CrossRef] [PubMed]

91. Jammalamadaga, V.S.; Abraham, P. Spectrum of Factors Triggering Endothelial Dysfunction in PIH. J. Clin. Diagn. Res. 2016, 10, BC14–BC17. [CrossRef] [PubMed]

92. Younes, S.T.; Maeda, K.J.; Sasser, J.; Ryan, M.J. The glucagon-like peptide 1 receptor agonist liratrateglu attenuates placental ischemia-induced hypertension. Am. J. Physiol. Circ. Physiol. 2020, 318, H72–H77. [CrossRef] [PubMed]

93. Ma, S.-L.; Tian, X.-Y.; Wang, Y.-Q.; Zhang, H.-F.; Zhang, L. Vitamin D Supplementation Prevents Placental Ischemia Induced Endothelial Dysfunction by Downregulating Placental Soluble FMS-Like Tyrosine Kinase-1. DNA Cell Biol. 2017, 36, 1134–1141. [CrossRef]

94. Zhu, M.; Ren, Z.; Possomato-Vieira, J.S.; Khalil, R.A. Restoring placental growth factor-soluble fms-like tyrosine kinase-1 balance reverses vascular hyper-reactivity and hypertension in pregnancy. Am. J. Physiol. Integr. Comp. Physiol. 2016, 311, R505–R521. [CrossRef]

95. Zhang, T.; Guo, D.; Zheng, W.; Dai, Q. Effects of S1PR2 antagonist on blood pressure and angiogenesis imbalance in preeclampsia rats. Mol. Med. Rep. 2021, 23, 456. [CrossRef] [PubMed]

96. Wang, G.-J.; Yang, Z.; Huai, J.; Xiang, Q.-Q. Pravastatin alleviates oxidative stress and decreases placental trophoblastic cell apoptosis through IL-6/STAT3 signaling pathway in preeclampsia rats. Mol. Med. Rep. 2020, 24, 12955–12962. [CrossRef] [PubMed]

97. Chimini, J.S.; Possomato-Vieira, J.S.; da Silva, M.L.S.; Dias-Junior, C.A. Placental nitric oxide formation and endothelium-dependent vasodilation underlie pravastatin effects against angiogenic imbalance, hypertension in pregnancy and intrauterine growth restriction. Basic Clin. Pharmacol. Toxicol. 2019, 124, 385–393. [CrossRef] [PubMed]

98. Ou, M.; Zhang, Q.; Zhao, H.; Shu, C. Polysaturated unsaturated Fatty Acid Diet and Uproregulation of Lipoxin A4 Reduce the Inflammatory Response of Preeclampsia. J. Proteome Res. 2020, 20, 357–368. [CrossRef] [PubMed]

99. Hu, J.; Zhang, J.; Zhu, B. Protective effect of metformin on a rat model of lipopolysaccharide-induced preeclampsia. Fundam. Clin. Pharmacol. 2019, 33, 649–658. [CrossRef] [PubMed]

100. Lefkou, E.; Varoudi, K.; Pombo, J.; Jurisic, A.; Jurisic, Z.; Contento, G.; Girardi, G. Triple therapy with pravastatin, low molecular weight heparin and low dose aspirin improves placental haemodynamics and pregnancy outcomes in obstetric antiphospholipid syndrome in women and men through a nitric oxide-dependent mechanism. Biochem. Pharmacol. 2020, 182, 114217. [CrossRef] [PubMed]

101. Purnamayanti, N.M.D.; Windu, S.C.; Poeranto, S. Effect of Nigella sativa Ethanol Extract on the Nitric Oxide Content and Renal Arteriole Diameter of a Pre-eclampsia Mouse Model. Eurasian J. Med. 2019, 50, 12538–12543. [CrossRef] [PubMed]

102. Xu, B.; Chen, X.; Ding, Y.; Chen, C.; Liu, T.; Zhang, H. Abnormal angiogenesis of placenta in progranulindeficient mice. Mol. Med. Rep. 2020, 22, 3482–3492. [CrossRef]

103. Lane, S.L.; Doyle, A.S.; Bales, E.S.; Lorca, R.A.; Julian, C.G.; Moore, L.G. Increased uterine artery blood flow in hypoxic murine pregnancy is not sufficient to prevent fetal growth restriction. Biomed Res. 2020, 12, 660–670. [CrossRef]

104. Zhang, S.; Zou, C.; Zhang, Q. Deletion of GIT1 Impacts eNOS Activity to Aggravate sFlt1–Induced Preeclampsia Phenotype in Mice. G3 Genes Genomes Genet. 2018, 8, 3377–3382. [CrossRef] [PubMed]

105. Makris, A.; Yeung, K.R.; Lim, S.M.; Sunderland, N.; Heffernan, S.; Thompson, J.; Iliopoulos, J.; Killingsworth, M.C.; Yong, J.; Xu, B.; et al. Placental Growth Factor Reduces Blood Pressure in a Uteroplacental Ischemia Model of Preeclampsia in Nonhuman Primates. Hypertension 2016, 67, 1263–1272. [CrossRef] [PubMed]

106. Walsh, S.K.; English, F.A.; Johns, E.J.; Kenny, L.C. Plasma-mediated vascular dysfunction in the reduced uterine perfusion pressure model of preeclampsia: A microvascular characterization. Hypertension 2009, 54, 345–351. [CrossRef]

107. Turanov, A.A.; Lo, A.; Hassler, M.R.; Makris, A.; Ashar-Patel, A.; Alterman, J.F.; Coles, A.H.; Haraszt, R.A.; Roux, L.; Godinho, B.M.D.C.; et al. RNAi modulation of placental sFLT1 for the treatment of preeclampsia. Nat. Biotechnol. 2018, 36, 1164–1173. [CrossRef]

108. Murphy, S.R.; LaMarca, B.; Cockrell, K.; Arany, M.; Granger, J.P. L-arginine supplementation abolishes the blood pressure and endothelin response to chronic increases in plasma sFlt1 in pregnant rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2012, 302, R259–R263. [CrossRef] [PubMed]

109. Amraoui, F.; Spijkers, L.; Lahsiniou, H.H.; Vogt, L.; Van Der Post, J.; Peters, S.; Afink, G.; Ris-Stalpers, C.; Born, B.-J.V.D. SFlt-1 Elevates Blood Pressure by Augmenting Endothelin-1-Mediated Vasoconstriction in Mice. PLoS ONE 2014, 9, e91897. [CrossRef]
185. Abbasi, H.; Dastgheib, S.A.; Hadadan, A.; Karimi-Zarchi, M.; Javaheri, A.; Meibodi, B.; Zanbagh, L.; Tabatabaei, R.S.; Neamateldeh, H. Association of Endothelial Nitric Oxide Synthase 894G > T Polymorphism with Preeclampsia Risk: A Systematic Review and Meta-Analysis based on 35 Studies. *Fetal Pediatr. Pathol.* 2020, 40, 455–470. [CrossRef]

186. Zeng, F.; Zhu, S.; Wong, M.; Yang, Z.; Tang, J.; Li, K.; Su, X. Associations between nitric oxide synthase 3 gene polymorphisms and preeclampsia risk: A meta-analysis. *Sci. Rep.* 2016, 6, 23407. [CrossRef]

187. Joshi, M.S.; Mineo, C.; Shaul, P.W.; Bauer, J.A. Biochemical consequences of the NOS3 Glu298Asp variation in human endothelium: Altered caveolar localization and impaired response to shear. *FASEB J.* 2007, 21, 2655–2663. [CrossRef] [PubMed]

188. Tesauro, M.; Thompson, W.C.; Rogliani, P.; Qi, L.; Chaudhary, P.P.; Moss, J. Intracellular processing of endothelial nitric oxide synthase isoforms associated with differences in severity of cardiopulmonary diseases: Cleavage of proteins with aspartate vs. glutamate at position. *Proc. Natl. Acad. Sci. USA* 2000, 97, 2832–2835. [CrossRef] [PubMed]

189. Sakar, M.N.; Atay, A.E.; Demir, S.; Bakır, V.L.; Demir, B.; Balsak, D.; Akay, E.; Ulusoy, A.I.; Verit, F.F. Association of endothelial nitric oxide synthase gene G894T polymorphism and serum nitric oxide levels in patients with preeclampsia and gestational hypertension. *J. Matern.-Neonatal Med.* 2014, 28, 1907–1911. [CrossRef]

190. Sharma, D.; Hussain, S.; Akhter, N.; Singh, A.; Trivedi, S.; Bhattacharjee, J. Endothelial nitric oxide synthase (eNOS) gene Glu298Asp polymorphism and expression in North Indian preeclamptic women. *Pregnancy Hypertens.* 2014, 4, 65–69. [CrossRef] [PubMed]

191. Muniz, L.; Luizoon, M.R.; Palei, A.C.; Lacchini, R.; Duarte, G.; Cavalli, R.C.; Tanus-Santos, J.E.; Sandrim, V.C. eNOS tag SNP haplotypes in hypertensive disorders of pregnancy. *DNA Cell Biol.* 2012, 31, 1665–1670. [CrossRef]

192. Sandrim, V.C.; Palei, A.C.T.; Sertorio, J.T.; Cavalli, R.C.; Duarte, G.; Tanus-Santos, J.E. Effects of eNOS polymorphisms on nitric oxide formation in healthy pregnant women and in pre-eclampsia. *Mol. Hum. Reprod.* 2010, 16, 506–510. [CrossRef]

193. Itoh, H.; Sagawa, N.; Nanno, H.; Mori, T.; Mukoyama, M.; Itoh, H.; Nakao, K. Impaired Guanosine 3′,5′ monophosphate in preeclampsia. *J. Matern.-Fetal. Med.* 1996, 5, 128–131. [CrossRef]

194. Lauria, M.R.; Standley, C.A.; Sorokin, Y.; Todt, J.C.; Bottoms, S.F.; Yelian, F.D.; Cotton, D.B. Brain natriuretic peptide and cyclic guanosine 3′,5′ monophosphate in pre-eclampsia. *J. Matern.-Fetal Med.* 2015, 28, 75, 40–44. [CrossRef]

195. Grunewald, C.; Nisell, H.; Carlstrom, K.; Kublickas, M.; Randmaa, I.; Nylund, L. Acute volume expansion in normal pregnancy and preeclampsia: Effects on plasma atrial natriuretic peptide (ANP) and cyclic guanosine monophosphate (cGMP) concentrations and feto-maternal circulation. *Acta Obstet. Gynecol. Scand.* 1994, 73, 294–299. [CrossRef]

196. Joshi, M.; Quinlin, L.; Dreyfus, M.; Ritter, J.; Tempé, J.-D. Plasma cyclic GMP concentrations and their relationship with changes of blood pressure levels in pre-eclampsia. *Acta Obstet. Gynecol. Scand.* 1996, 75, 40–44. [CrossRef]

197. Schiessl, B.; Strasburger, C.; Bidlingmaier, M.; Mylonas, I.; Jeschke, U.; Kainer, F.; Friese, K. Plasma- and urine concentrations of nitrite/nitrate and cyclic Guanosinemonophosphate in intraterine growth restricted and preeclamptic pregnancies. *Arch. Gynecol. Obstet.* 2006, 274, 150–154. [CrossRef] [PubMed]

198. Boccadoro, P.; Soregaroli, M.; Aiello, S.; Noris, M.; Donadelli, R.; Lojacono, A.; Benigni, A. Systemic and feto-maternal nitric oxide synthesis in normal pregnancy and preeclampsia. *BJOG Int. J. Obstet. Gynaecol.* 1996, 103, 879–886. [CrossRef] [PubMed]

199. Grunewald, C.; Nisell, H.; Carlstrom, K.; Kublickas, M.; Randmaa, I.; Nylund, L. Acute volume expansion in normal pregnancy and preeclampsia: Effects on plasma atrial natriuretic peptide (ANP) and cyclic guanosine monophosphate (cGMP) concentrations and feto-maternal circulation. *Acta Obstet. Gynecol. Scand.* 1994, 73, 294–299. [CrossRef]

200. Itoh, H.; Sagawa, N.; Nanno, H.; Mori, T.; Mukoyama, M.; Itoh, H.; Nakao, K. Impaired Guanosine 3′,5′-Cyclic Phosphate Production in Severe Pregnancy-Induced Hypertension with High Plasma Levels of Atrial and Brain Natriuretic Peptides. *Endocr. J.* 1997, 44, 389–393. [CrossRef] [PubMed]

201. Sandrim, V.C.; Palei, A.C.; Sertó, J.T.; Amaral, L.M.; Cavalli, R.C.; Tanus-Santos, J.E. Alterations in cyclic GMP levels in preeclampsia may reflect increased B-type natriuretic peptide levels and not impaired nitric oxide activity. *Clin. Biochem.* 2011, 44, 1012–1014. [CrossRef] [PubMed]

202. Schneider, F.; Lutun, P.; Baldauf, J.-J.; Quirin, L.; Dreyfus, M.; Ritter, J.; Tempé, J.-D. Plasma cyclic GMP concentrations and their relationship with changes of blood pressure levels in pre-eclampsia. *Acta Obstet. Gynecol. Scand.* 1996, 75, 40–44. [CrossRef] [PubMed]

203. Dusse, L.M.; Alpoin, P.N.; Lvaleed, B.A.; de Sousa, L.P.; Carvalho, M.; Gomes, K.B. Is there a link between endothelial dysfunction, coagulation activation and nitric oxide synthesis in preeclampsia? *Clin. Chim. Acta* 2013, 415, 226–229. [CrossRef]

204. Lopez-Jaramillo, P.; Narváez, M.; Calle, A.; Rivera, J.; Jacome, P.; Ruano, C.; Nava, E. Cyclic guanosine 3′,5′ monophosphate concentrations in pre-eclampsia: Effects of hydralazine. *Br. J. Obset. Gynecol.* 1996, 103, 33–38. [CrossRef] [PubMed]

205. Manninen, A.; Vuorinen, P.; Lappila, P.; Tuimala, R.; Vapaatalo, H. Atrial Natriuretic Peptide and Cyclic Guanosine-3′,5′-monophosphate in Hypertensive Pregnancy and during Nifedipine Treatment. *Pharmacol. Toxicol.* 1994, 74, 153–157. [CrossRef] [PubMed]

206. Okuno, S.; Hamada, H.; Yasukuta, M.; Watanabe, H.; Fujiki, Y.; Yamada, N.; Sohda, S.; Kubo, T. Brain Natriuretic Peptide (BNP) and Cyclic Guanosine Monophosphate (cGMP) Levels in Normal Pregnancy and Preeclampsia. *J. Obstet. Gynecol. Res.* 1999, 25, 407–410. [CrossRef] [PubMed]

207. Chen, J.; Ren, W.; Lin, L.; Zeng, S.; Huang, L.; Tang, J.; Bi, S.; Pan, J.; Chen, D.; Du, L. Abnormal GMP-dependent protein kinase I-mediated decidualization in preeclampsia. *Hypertens. Res.* 2021, 44, 318–324. [CrossRef] [PubMed]

208. Gao, Q.; Tang, J.; Li, N.; Zhou, X.; Zhu, X.; Li, W.; Liu, B.; Feng, X.; Tao, J.; Han, B.; et al. New concept for the development of hypertension in preeclampsia. *Oncotarget* 2016, 7, 78387–78395. [CrossRef]

209. Coats, L.E.; Bamrick-Fernandez, D.R.; Ariatti, A.M.; Bakrania, B.A.; Rawls, A.Z.; Ojeda, N.B.; Alexander, B.T. Stimulation of soluble guanylate cyclase diminishes intrauterine growth restriction in a rat model of placental ischemia. *Am. J. Physiol. Integr. Comp. Physiol.* 2021, 320, R149–R161. [CrossRef] [PubMed]

210. Takushima, S.; Nishi, Y.; Nonoshita, A.; Mifune, H.; Hirata, R.; Tanaka, E.; Doi, R.; Hori, D.; Kamura, T.; Usuijima, K. Changes in the nitric oxide-soluble guanylate cyclase system and natriuretic peptide receptor system in placenta of pregnant Dahl salt-sensitive rats. *J. Obstet. Gynecol. Res.* 2014, 41, 540–550. [CrossRef] [PubMed]
Turgut, N.H.; Temiz, T.K.; Turgut, B.; Karadas, B.; Parlak, M.; Bagcivan, I. Investigation of the role of the NO-cGMP pathway on YC-1 and DEA/NO effects on thoracic aorta smooth muscle responses in a rat preeclampsia model. Can. J. Physiol. Pharmacol. 2013, 91, 797–803. [CrossRef]

Sandner, P.; Zimmer, D.P.; Milne, G.T.; Follmann, M.; Hobbs, A.; Stasch, J.-P. Soluble Guanylate Cyclase Stimulators and Activators. Handb. Exp. Pharmacol. 2018, 355–394. [CrossRef]

Bakrania, B.A.; Spradley, F.T.; Patel, B.R.; Travis, A.B.; Sandner, P.; Granger, J.P. Soluble Guanylate Cyclase Activators Increase cGMP Expression and Improve Vascular Function and Placental Ischemia-Induced Hypertension. FASEB J. 2019, 33, 865.13. [CrossRef]

Coats, L.E.; Bakrania, B.A.; Barakick-Fernandez, D.R.; Ariatti, A.M.; Rawls, A.Z.; Ojeda, N.B.; Alexander, B.T. Soluble guanylate cyclase stimulation in late gestation does not mitigate asymmetric intrauterine growth restriction or cardiovascular risk induced by placental ischemia in the rat. Am. J. Physiol. 2021, 320, H1923–H1934. [CrossRef]

Da Costa, B.P.; Scocco, C.; De Figueiredo, C.P.; Guimaraes, J.A.; Da Costa, B.E.P.; De Figueiredo, C.E.P. Maternal medicine: Increased serum phosphodiesterase activity in women with pre-eclampsia. BJOG Int. J. Obstet. 2006, 113, 577–579. [CrossRef] [PubMed]

George, E.; Palei, A.C.; Dent, E.A.; Granger, J.P. Sildenafil attenuates placental ischemia-induced hypertension. Am. J. Physiol. Integr. Comp. Physiol. 2013, 305, R397–R403. [CrossRef] [PubMed]

Samangaya, R.A.; Mires, G.; Shennan, A.; Skillern, L.; Howe, D.; McLeod, A.; Baker, P.N. A Randomised, Double-Blinded, Placebo-Controlled Study of the Phosphodiesterase Type 5 Inhibitor Sildenafil for the Treatment of Preeclampsia. Hypertens. Pregnancy 2009, 28, 369–382. [CrossRef] [PubMed]

Trapani, A.J.; Gonçalves, L.F.; Trapani, T.F.; Franco, M.J.; Galluzzo, R.N.; Pires, M.M.S. Comparison between transdermal nitroglycerin and sildenafil citrate infusion in intrauterine growth restriction: Effects on uterine, umbilical and fetal cerebral artery pulsatility indices. Ultrasound Obstet. Gynecol. 2016, 48, 61–65. [CrossRef] [PubMed]

Trapani, A., Jr.; Gonçalves, L.F.; Trapani, T.F.; Vieira, S.; Pires, M.; Pires, M.M.S. Perinatal and Hemodynamic Evaluation of Sildenafil Citrate for Preeclampsia Treatment: A Randomized Controlled Trial. Obstet. Gynecol. 2016, 128, 253–259. [CrossRef]

Groom, K.M.; McCowen, L.M.; Mackay, L.K.; Lee, A.C.; Gardener, G.; Unterscheider, J.; Sekar, R.; Dickinson, J.E.; Muller, P.; Reid, R.A.; et al. STRIDER NZAUs: A multicentre randomised controlled trial of sildenafil therapy in early-onset fetal growth restriction. BJOG Int. J. Obstet. Gynecol. 2019, 126, 997–1006. [CrossRef]

Pels, A.; Derks, J.; Elvan-Taspinar, A.; van Drongelen, J.; de Boer, M.; Duvekot, H.; van Laar, J.; van Eyck, J.; Al-Nasiry, S.; Sueters, M.; et al. Maternal Sildenafil vs Placebo in Pregnant Women with Severe Early-Onset Fetal Growth Restriction: A Randomized Clinical Trial. JAMA Netw. Open 2020, 3, e205323. [CrossRef]

Ferreira, R.D.D.S.; Negri, R.; Bernardo, W.M.; Simões, R.; Piato, S. The effects of sildenafil in maternal and fetal outcomes in pregnancy: A systematic review and meta-analysis. PloS ONE 2019, 14, e0219732. [CrossRef]

Furushashi, F.; Tanaka, H.; Maki, S.; Tsuji, M.; Magawa, S.; Kaneda, M.K.; Nii, M.; Tanaka, K.; Ogura, T.; Nishimura, Y.; et al. Tadalafil treatment for preeclampsia (medication in preeclampsia; MIE): A multicenter phase II clinical trial. J. Matern.-Neonatal Med. 2019, 34, 3709–3715. [CrossRef]

Furushashi, F.H.; Tanaka, H.; Kaneda, M.K.; Maki, S.; Nii, M.; Umekawa, T.; Osato, K.; Kaminoto, Y.; Ikeda, T. Safety trial of tadalafil administered for the treatment of preeclampsia. J. Matern.-Neonatal Med. 2018, 33, 167–170. [CrossRef]

Herraz, S.; Pellicer, B.; Serra, V.; Cauli, O.; Cortijo, J.; Felipo, V.; Pellicer, A. Sildenafil citrate improves perinatal outcome in fetuses from pre-eclamptic rats. J. Matern.-Neonatal Med. 2012, 119, 1394–1402. [CrossRef] [PubMed]

Li, Y.; Yang, N.; Wang, B.; Niu, X.; Cai, W.; Li, Y.; Li, Y.; Chen, S. Effect and mechanism of prophylactic use of tadalafil during pregnancy on L-NAME-induced preeclampsia-like rats. Placenta 2020, 99, 35–44. [CrossRef] [PubMed]

Motta, C.; Crosso, C.; Zanuzzi, C.; Molinero, D.; Picco, N.; Bellingeri, R.; Alustiza, F.; Barbeito, C.; Vivas, A.; Romanini, M. Effect of Sildenafil on Pre-Eclampsia-Like Mouse Model Induced By L-Name. Reprod. Domest. Anim. 2015, 50, 611–616. [CrossRef] [PubMed]

Ramesar, S.; Mackraj, I.; Gathiram, P.; Moodley, J. Sildenafil citrate improves fetal outcomes in pregnant, L-NAME treated, Sprague–Dawley rats. Eur. J. Reprod. Biol. J. Reprod. Biol. 2009, 149, 22–26. [CrossRef]

Soobryan, N.; Murugesan, S.; Phoswa, W.; Gathiram, P.; Moodley, J.; Mackraj, I. The effects of sildenafil citrate on uterine angiogenic status and serum inflammatory markers in an L-NAME rat model of pre-eclampsia. Eur. J. Pharmacol. 2016, 795, 101–107. [CrossRef]

Yoshikawa, K.; Umekawa, T.; Maki, S.; Kubo, M.; Nii, M.; Tanaka, K.; Tanaka, H.; Osato, K.; Kaminoto, Y.; Kondo, E.; et al. Tadalafil Improves L-NG-Nitroarginine Methyl Ester-Induced Preeclampsia with Fetal Growth Restriction-Like Symptoms in Pregnant Mice. Am. J. Hypertens. 2017, 31, 89–96. [CrossRef]

Gillis, E.E.; Mooney, J.N.; Garrett, M.R.; Granger, J.P.; Sasser, J.M. Sildenafil Treatment Ameliorates the Maternal Syndrome of Preeclampsia and Rescues Fetal Growth in the Dahl Salt–Sensitive Rat. Hypertension 2016, 67, 647–653. [CrossRef]

Stanley, J.L.; Andersson, I.J.; Poudel, R.; Rueda-Clausen, C.F.; Sibley, C.P.; Davidge, S.T.; Baker, P.N. Sildenafil Citrate Rescues Fetal Growth in the Cathexol-O-Methyl Transferase Knockout Mouse Model. Hypertension 2012, 59, 1021–1028. [CrossRef]